Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of ofatumumab in relapsing multiple sclerosis (Japan)
jRCT2080224590Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label, single-arm trial of ofatumumab in multiple sclerosis (MS), sponsored by Novartis. Started Mar 2019; status: completed.
02
Drugs
ofatumumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on jRCT2080224590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224590.